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Background:  Vorapaxar inhibits PAR-1 on platelets and vascular endothelium reducing ischemic events and peripheral artery 
revascularization (PR). We investigated whether the reduction in PR with vorapaxar varied by reason or type of revascularization.
methods:  TRA2°P-TIMI 50 was a multinational, randomized, double-blind, placebo controlled trial of vorapaxar in stable patients with 
established atherosclerosis. We evaluated the reasons and types of PR among patients with a history of PAD (n=5,845).
results:  A total of 934 PR procedures occurred over 2.5 y (median). Indications for PR included claudication in 60%, chronic critical 
limb ischemia (CLI) in 22%, and acute limb ischemia (ALI) in 13%. The most frequent mode of PR was endovascular followed by surgical 
bypass. Amputation occurred in 8% of subjects. There was a consistent pattern of reduction of PR with vorapaxar across indication with a 
significant reduction in PR for claudication (HR 0.84, 95% CI 0.71 - 0.99, p=0.04, Fig 1A). Vorapaxar significantly reduced surgical PR (HR 
0.59, 95% CI 0.47 -0.74, p ≤ 0.001, Fig 1B) with a consistent trend for endovascular and amputation (Fig 1B).
conclusion:  Vorapaxar reduced the need for peripheral revascularization, including a significant reduction in surgical PR. There was a 
significant reduction in PR for claudication and trends for a reduced rate of PR for CLI and ALI implicating a favorable affect of vorapaxar 
on mechanisms contributing to worsening atherothrombosis in patients with established PAD.
 
